Articles from Brenus Pharma

Brenus Pharma, a clinical-stage biotechnology company developing first-in-class in vivo immunotherapies for solid tumors, announced the appointment of Olivera J. Finn, Distinguished Professor at the University of Pittsburgh School of Medicine, to its Scientific Advisory Board (SAB).

Brenus Pharma today announced that first patients have been successfully dosed in its first-in-human clinical trial evaluating STC-1010, the company’s lead in vivo immunotherapy candidate developed through its proprietary off-the-shelf platform. Three patients have already been enrolled in the study. The first completed eight weeks of treatment with no adverse events attributed to the investigational therapy. This trial targets patients with unresectable, locally advanced or metastatic colorectal cancer (CRC) — the second leading cause of cancer-related death worldwide — for whom chemotherapy remains the predominant treatment option.

Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus’ lead candidate for colorectal cancer.

Brenus Pharma, a French clinical-stage biotechnology company, presented new preclinical data on its lead immunotherapy candidate, STC-1010, during the Late-Breaking Research: Immunology 3 session at the AACR Annual Meeting 2025, held April 25–30 in Chicago, IL.

Brenus Pharma has announced the publication of a scientific article describing its new “off-the-shelf” cancer treatment in “Frontiers in Oncology” Section Cancer Immunity and Immunotherapy.

Brenus Pharma, a biotech company specializing in the development of cancer vaccines, announces the completion of a $25 million Series A financing round.

During its annual event "BIG UP", French Tech Saint-Etienne Lyon awarded the BIG Start-up of the Year trophy, honoring a start-up that exemplifies the region's innovation and richness.

A year ago, Brenus was selected to participate in CDL Cancer, a global mentorship program for massively scalable, science-based and innovative companies accelerating cancer treatment.

Brenus Pharma, French biotech developing its proprietary discovery platform: “Stimulated-Tumor-Cell” (STC), has presented the study design of “BreAK-CRC” First-in-human of STC-1010, Brenus’ lead candidate, during ASCO annual meeting (31st May – 4th June 2024) - Trials in Progress poster session, in Chicago.

Brenus Pharma unveils groundbreaking results during the American Association Cancer Research (AACR) Annual meeting 2024 – San Diego (April 5-10).

Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech. The ceremony took place on Monday, March 25th in Paris, gathering key players in the French health innovation ecosystem.

Brenus Pharma announces the financing of nearly 5 million euros for its STC-1010 project as the winner of the "Innovations in Biotherapy and Bioproduction" call for proposals from France 2030. Operated on behalf of the French government by Bpifrance, this support aims to catalyze and maintain excellence in biotherapy research and places Brenus Pharma among the key players of French Biotherapy.

Brenus Pharma has successfully joined the Paris Saclay Cancer Cluster (PSCC), the first national Onco-cluster. This membership positions Brenus at the heart of the European initiative to accelerate and valorize innovation in oncology.

Brenus Pharma announces that pre-clinical advancements of its inaugural research program were presented at the 7th CICON (International Cancer Immunotherapy) Conference in Milan, Italy (September 20-23) and will be showcased at the 38th Annual SITC (Society for Immunotherapy of Cancer) Congress in San Diego, CA, USA (November 1-5)

Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee.

Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma's STC (Stimulated Tumor-Cells) Technology Platform.

The French Blood Establishment (EFS) and Brenus Pharma announce their strategic partnership in the bioproduction of innovative therapy drugs (ITD), highlighting French expertise. This collaboration is part of a shared vision: developing the French bioproduction sector nationally and internationally.

BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced today the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives.